Chinese tech giant ByteDance – best known as the parent of social media app TikTok – has completed a $290 million financing ...

Curium's radioligand therapy Bexlutry has been approved in the US as a generic – or 'radioligand equivalent' (RLE) – of ...

The expedited IND programme will allow trial sponsors to partner with a set of qualified research institutions (QRIs) to review IND applications in rolling parts, rather than all at once, and aims to ...

On World Diabetes Day, Sanofi is celebrating an approval recommendation in the EU for Teizeild, a first-in-class drug designed to delay the progression of type 1 diabetes (T1D). The EMA's human ...

A pharmaceutical company sends a patient a reminder to refill a prescription. A specialty pharmacy calls to coordinate ...

There's been a lot of talk about forging closer ties between Europe and Canada in response to the US' aggressive disruption of international trade. Now, two senior figures in Canada's life sciences ...

HHS has moved to firm up the leadership at the FDA after a long period of uncertainty and disruption, upgrading the heads of the agency's centres governing drugs and biologics from acting to permanent ...

The Danish Group stated that the new corporate culture – dubbed 'The Novo Way' – centres around four Cs; namely, customer ...

Hard on the heels of a big disappointment in its cardiovascular pipeline, Novartis has suffered another – this time for its highly anticipated neuromuscular disease therapy del-desiran. The company's ...

Roche is preparing to file one BTK-targeting drug for approval, and has just added another with potential across oncology, immunology, and neurology via a deal with Nurix Therapeutics. The licensing ...

GSK has continued its drive to bulk up its pipeline, taking global rights to a T-cell engager (TCE) for multiple myeloma, ...

GSK reported good clinical trial results with two of its lung cancer therapies – Jideytro and risvutatug rezetecan (ris-rez) ...